The Aquaporin go-to-market strategy is centered around Strategic Commercial Partnerships (SCPs) with committed development partners.
The expected role for a commercial partner is to develop treatment systems based on Aquaporin membranes and market the systems for specific applications or geographies.
For Aquaporin, the benefit of this model is shorter time to market and mitigation of risk in commercialization. For partners, Aquaporin in turn offers favorable commercial terms and first-mover advantage.
Please contact us below, with inquiries about becoming a partner.